$13.23
1.73% today
Nasdaq, Feb 05, 04:48 pm CET
ISIN
US2681582019
Symbol
DVAX

Dynavax Technologies Corporation Stock price

$13.00
+0.24 1.88% 1M
+2.93 29.10% 6M
+0.23 1.80% YTD
+0.21 1.64% 1Y
+0.38 3.01% 3Y
+7.78 149.04% 5Y
-3.18 19.65% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.06 0.46%
ISIN
US2681582019
Symbol
DVAX
Sector
Industry

Key metrics

Market capitalization $1.71b
Enterprise Value $1.20b
P/E (TTM) P/E ratio 99.77
EV/FCF (TTM) EV/FCF 52.91
EV/Sales (TTM) EV/Sales 4.60
P/S ratio (TTM) P/S ratio 6.55
P/B ratio (TTM) P/B ratio 2.51
Revenue growth (TTM) Revenue growth -27.79%
Revenue (TTM) Revenue $260.81m
EBIT (operating result TTM) EBIT $-7.44m
Free Cash Flow (TTM) Free Cash Flow $22.67m
Cash position $763.99m
EPS (TTM) EPS $0.13
P/E forward 63.76
P/S forward 6.14
EV/Sales forward 4.31
Short interest 17.80%
Show more

Is Dynavax Technologies Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Dynavax Technologies Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Dynavax Technologies Corporation forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Dynavax Technologies Corporation forecast:

Buy
83%
Hold
17%

Financial data from Dynavax Technologies Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
261 261
28% 28%
100%
- Direct Costs 45 45
62% 62%
17%
216 216
11% 11%
83%
- Selling and Administrative Expenses 159 159
9% 9%
61%
- Research and Development Expense 57 57
6% 6%
22%
0.50 0.50
99% 99%
0%
- Depreciation and Amortization 7.94 7.94
17% 17%
3%
EBIT (Operating Income) EBIT -7.44 -7.44
120% 120%
-3%
Net Profit 20 20
66% 66%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Dynavax Technologies Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dynavax Technologies Corporation Stock News

Neutral
PRNewsWire
9 days ago
Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting Intends to Seek Stockholder Approval for Declassification of Board at 2025 Annual Meeting EMERYVILLE, Calif. , Jan. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) (the "Company"), a commercial-stage biopharmaceutical company developing and commercializin...
Neutral
PRNewsWire
23 days ago
Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $30 million contract with U.S. Department of Defense to advance plague vaccine program Cash, cash equivalents and marketable securities were approximately $714 million as of December 31, 2024 EMERYVILLE,...
Neutral
PRNewsWire
2 months ago
EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m.
More Dynavax Technologies Corporation News

Company Profile

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Head office United States
CEO Ryan Spencer
Employees 408
Founded 1996
Website www.dynavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today